A20 as a novel immunoregulatory target for neuroinflammation.

Neuroinflammation contributes to many CNS disorders, whereas broad anti-inflammatory treatments can compromise host defenses. A20, encoded by TNFAIP3, is a ubiquitin-editing immunoregulatory protein that restrains NF-κB signaling. Beyond its catalytic domains, A20 functions with TAX1BP1, ITCH and RNF11 to terminate inflammatory signaling and regulate downstream nodes such as TRAF6. Cell-specific and disease-model studies indicate that impaired A20 activity prolongs glial activation, inflammasome cytokine release, chemokine production and blood-brain barrier disruption, whereas enhancing A20 promotes inflammatory resolution. A20 is a network-level checkpoint; but drug development should distinguish effects on expression, complex assembly or substrate signaling while preserving cell- and time-specific immune control.